Contact Dermatitis (CD) - Epidemiology Forecast–2030

DelveInsight’s ‘Contact Dermatitis (CD) - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted Contact Dermatitis (CD) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Dermatitis (CD) Understanding
Contact dermatitis (CD) is a type of eczema triggered by contact with a particular substance in the environment that the person is allergic to, it may react by causing the skin to itch and become red. Eczema is the name for a group of conditions that cause skin to become dry and irritated. CD usually improves or clears up completely if the substance causing the problem is identified and avoided. Treatments are also available to help ease the symptoms.

CD is a common inflammatory skin condition characterized by erythematous and pruritic skin lesions that occur after contact with a foreign substance. The most common substances that cause CD include poison ivy, nickel, and fragrances. CD usually leads to erythema and scaling with visible borders. Itching and discomfort may also occur.

Clinical symptoms depend primarily on whether the dermatitis is acute or chronic, as well as on the toxin involved, type of contact, pathomechanism, and localization, among other factors. Although all types of dermatitis generally share common features, the classic eczematous stages in CD are most readily identifiable.

Acute CD is characterized by pathological symptoms over the entire lesion:
• Mild form: erythema at the site of exposure to the toxin, contact traces, and itching are possible.
• Severe form: ranging from vesicular papules to blisters, usually causing strong itching. A feeling of tightness of the skin and even pain may occur. Blister rupture is followed by weeping, scab formation, and later by scaliness. Spreading reactions are possible in the case of an allergic trigger.

CD is a common skin problem occurring in 15–20% of people. Irritant Contact Dermatitis (ICD) is more common (80%) and can occur in anyone, especially after repeated exposure. Allergic contact dermatitis (ACD), on the other hand, is seen in genetically predisposed and previously sensitized individuals who react to even low concentrations of the agent. Cosmetics, medicines, clothes dyes, as well as foods, rubber and poison ivy are common causes of ACD. Any topical cream or ointment may contain chemicals that irritate the skin.

Contact Dermatitis (CD) Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Population of Contact Dermatitis, Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution, Gender-specific Diagnosed Prevalent Population of Contact Dermatitis, Age-specific Diagnosed Prevalent Population of Contact Dermatitis and Type-specific Diagnosed Prevalent Population of Contact Dermatitis in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Contact Dermatitis (CD) Detailed Epidemiology Segmentation
• The total diagnosed prevalent population of CD in the 7 major markets was found to be 43,359,201 in 2017.
• In case of CD in the United States, the diagnosed prevalent cases were found to be 13,786,942 in 2017.
• It was found that in the United States the number of cases of ICD and ACD were 11,029,554 and 2,757,388 respectively in 2017.
• In addition, the number of cases of acute, sub-acute and chronic type of CD were 7,611,771, 2,903,530 and 3,271,641 respectively in 2017, in the United States.
• Gender-specific data of the United States suggests that the number of cases of CD in males and females were 4,825,430 and 8,961,513 respectively in 2017.
• Age-specific data for CD suggests that in the United States the maximum number of cases of CD were found in the age group of 46–60 with 4,411,822 cases in 2017, while the lowest number of cases were found in the age group 75+ with 275,739 cases in 2017.
• In the EU5 countries, the diagnosed prevalence of CD was found to be maximum in Germany with 6,645,210 cases, followed by France with 5,481,080 cases in 2017. While, the least number of cases were found in Spain, with 1,982,709 cases in 2017.
• In Japan, the diagnosed prevalence of CD was found to be 5,107,575 in 2017.

Scope of the Report
• The report covers the descriptive overview of Contact Dermatitis (CD), explaining its causes, signs and symptoms, pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Contact Dermatitis (CD).
• The report provides the segmentation of the disease epidemiology for the 7MM by Total Diagnosed Prevalent Population of Contact Dermatitis (CD) and Severity-based Diagnosed Prevalent Population of Contact Dermatitis (CD).

Report Highlights
• Eleven Year Forecast of Contact Dermatitis (CD)
• 7MM Coverage
• Total Diagnosed Prevalent Population of Contact Dermatitis (CD)
• DelveInsight has analyzed type-based data for Contact Dermatitis (CD). Contact Dermatitis can be of two types based on this data, namely, Irritant Contact Dermatitis (ICD) and Allergic Contact Dermatitis (ACD).
• Type-specific data based on clinical and biological evolution of Contact Dermatitis (CD) has also been analyzed by Delvelnsight. On this basis, Contact Dermatitis can be divided as Acute, Sub-acute and Chronic type.
• In addition, Delvelnsight has also analyzed gender-specific data for Contact Dermatitis (CD), which clearly suggests that CD is more prevalent among females than males.
• The report also encompasses another major segment, i.e., Age-specific Diagnosed Prevalent Population of Contact Dermatitis (CD), wherein various age groups have been considered, such as 0–17, 18–29, 30–45, 46–60, 61–75 and 75+. It has been found that CD majorly affects patients whose age is 40 years or above.
• Expected Launch of a potential therapy, EB01 (Edesa Biotech), may increase the market size in the coming years, assisted by an increase in diagnosed prevalent population of Contact Dermatitis (CD).
• The current treatment of Contact Dermatitis (CD) is mainly dominated by the use of off-label therapies, which includes Topical Corticosteroids (Clobetasol and Triamcinolone) and Emollients, Topical Immunosupressants (Pimecromilus and Tacrolimus), Systemic Immunosupressants (Antihistamines) and Corticosteroids and Others (Antiseptics, Topical Antibiotics, Phototherapy and Other Immunosupressants).

Key Questions Answered
• What is the disease risk, burden and unmet needs of Contact Dermatitis (CD)?
• What is the historical Contact Dermatitis (CD) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Contact Dermatitis (CD) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Contact Dermatitis (CD)?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Contact Dermatitis (CD) during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Reasons to buy
The Contact Dermatitis (CD) report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Contact Dermatitis (CD) market.
• Quantify patient share distribution in the 7MM for Contact Dermatitis (CD).
• The Contact Dermatitis (CD) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Contact Dermatitis (CD) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030


1 Key Insights
2 Contact Dermatitis Overview at a Glance
3 Executive Summary of Contact Dermatitis (CD)
4 Disease Background and Overview: Contact Dermatitis (CD)
4.1 Types
4.1.1 Irritant Contact Dermatitis (ICD)
4.1.2 Allergic Contact Dermatitis (ACD)
4.1.3 Contact Urticaria
4.2 Causes
4.2.1 Metals
4.2.2 Fragrances
4.2.3 Antibacterial Ointments
4.2.4 Formaldehyde
4.2.5 Isothiazolinones
4.2.6 Cocamidopropyl Betaine
4.2.7 Paraphenylene-Diamine
4.3 Symptoms
4.4 Pathophysiology
4.5 Diagnosis
5 Algorithm for Diagnosis and Management of CD
6 Diagnostic Guidelines by American Academy of Allergy Asthma & Immunology (AAAAI)
6.1 Clinical Evaluation
6.2 Patch testing recommendations
6.3 Sources of exposure to clinically relevant allergens
6.4 Topical medicinal CD
6.5 Special populations
6.5.1 CD in children
6.5.2 Occupational CD
7 Diagnostic Guidelines by the British Association of Dermatologists (BAD)
7.1 Assessment and Investigation
7.2 Diagnostic Tests (Diagnosis)
7.2.1 Preparation of the patient
7.2.2 Patch testing
7.2.3 Timing of patch test readings
7.2.4 Reading and relevance of positive reactions
7.2.5 Photopatch testing
7.2.6 Open patch testing
8 Epidemiology and Patient Population: Key Findings
8.1 7 MM 7 MM Total Diagnosed Prevalent Population of Contact Dermatitis
9 Country Wise-Epidemiology of Contact Dermatitis
9.1 United States
9.1.1 Assumptions and Rationale
9.1.2 Total Diagnosed Prevalent Population of Contact Dermatitis in the United States
9.1.3 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in the United States
9.1.4 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States
9.1.5 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States
9.1.6 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States
9.2 EU5 Countries
9.2.1 Assumptions and Rationale
9.3 Germany
9.3.1 Total Diagnosed Prevalent Population of Contact Dermatitis in Germany
9.3.2 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Germany
9.3.3 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany
9.3.4 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany
9.3.5 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany
9.4 France
9.4.1 Total Diagnosed Prevalent Population of Contact Dermatitis in France
9.4.2 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in France
9.4.3 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in France
9.4.4 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in France
9.4.5 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in France
9.5 Italy
9.5.1 Total Diagnosed Prevalent Population of Contact Dermatitis in Italy
9.5.2 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Italy
9.5.3 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy
9.5.4 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy
9.5.5 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy
9.6 Spain
9.6.1 Total Diagnosed Prevalent Population of Contact Dermatitis in Spain
9.6.2 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Spain
9.6.3 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain
9.6.4 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain
9.6.5 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain
9.7 United Kingdom
9.7.1 Total Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom
9.7.2 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in the United Kingdom
9.7.3 Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom
9.7.4 Age-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom
9.7.5 Type-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom
9.8 Japan
9.8.1 Assumptions and Rationale
9.8.2 Total Diagnosed Prevalent Population of Contact Dermatitis in Japan
9.8.3 Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Japan
10 Appendix
10.1 Bibliography
10.2 Report Methodology
11 DelveInsight Capabilities
12 Disclaimer
13 About DelveInsight
Table 1: Summary of Contact Dermatitis, Market, Epidemiology and Key Events (2017–2030)
Table 2: Classical clinical forms of CD
Table 3: Features that distinguishes between Irritant and Allergic Contact Dermatitis
Table 4: Exogenous and endogenous factors affecting clinical characteristics of CD
Table 5: The most important non-eczematous symptoms of contact allergic reactions
Table 6: Differential Diagnosis of Contact Dermatitis
Table 7: Scoring of patch test reactions according to the International Contact Dermatitis Research Group recommendations
Table 8: Total Diagnosed Prevalent Population of Contact Dermatitis in the 7 MM (2017–2030)
Table 9: Total Diagnosed Prevalent Population of Contact Dermatitis in the United States (2017–2030)
Table 10: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in the US (2017–2030)
Table 11: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States (2017–2030)
Table 12: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States (2017–2030)
Table 13: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in the United States (2017–2030)
Table 14: Total Diagnosed Prevalent Population of Contact Dermatitis in Germany (2017–2030)
Table 15: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in Germany (2017–2030)
Table 16: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany (2017–2030)
Table 17: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany (2017–2030)
Table 18: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Germany (2017–2030)
Table 19: Total Diagnosed Prevalent Population of Contact Dermatitis in France (2017–2030)
Table 20: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in France (2017–2030)
Table 21: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in France (2017–2030)
Table 22: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in France (2017–2030)
Table 23: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in France (2017–2030)
Table 24: Total Diagnosed Prevalent Population of Contact Dermatitis in Italy (2017–2030)
Table 25: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in Italy (2017–2030)
Table 26: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy (2017–2030)
Table 27: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy (2017–2030)
Table 28: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Italy (2017–2030)
Table 29: Total Diagnosed Prevalent Population of Contact Dermatitis in Spain (2017–2030)
Table 30: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in Spain (2017–2030)
Table 31: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain (2017–2030)
Table 32: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain (2017–2030)
Table 33: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Spain (2017–2030)
Table 34: Total Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom (2017–2030)
Table 35: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in the UK (2017–2030)
Table 36: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom (2017–2030)
Table 37: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom (2017–2030)
Table 38: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom (2017–2030)
Table 39: Total Diagnosed Prevalent Population of Contact Dermatitis in Japan (2017–2030)
Table 40: Type-specific Diagnosed Prevalent Population of CD Based on Clinical and Biological Evolution in Japan (2017–2030)
Table 41: Gender-specific Diagnosed Prevalent Population of Contact Dermatitis in Japan (2017–2030)
Table 42: Age-specific Diagnosed Prevalent Population of Contact Dermatitis in Japan (2017–2030)
Table 43: Type-specific Diagnosed Prevalent Population of Contact Dermatitis in Japan (2017–2030)
Figure 1: Pathophysiology of Allergic and Irritant CD
Figure 2: Algorithm for Diagnosis and Management of CD
Figure 3: Total Diagnosed Prevalent Population of Contact Dermatitis in the 7 MM (2017–2030)
Figure 4: Total Diagnosed Prevalent Population of Contact Dermatitis in the United States (2017–2030)
Figure 5: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in the United States (2017–2030)
Figure 6: Gender-specific Diagnosed Prevalent Population of CD in the United States (2017–2030)
Figure 7: Age-specific Diagnosed Prevalent Population of CD in the United States (2017–2030)
Figure 8: Type-specific Diagnosed Prevalent Population of CD in the United States (2017–2030)
Figure 9: Total Diagnosed Prevalent Population of Contact Dermatitis in Germany (2017–2030)
Figure 10: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Germany (2017–2030)
Figure 11: Gender-specific Diagnosed Prevalent Population of CD in Germany (2017–2030)
Figure 12: Age-specific Diagnosed Prevalent Population of CD in Germany (2017–2030)
Figure 13: Type-specific Diagnosed Prevalent Population of CD in Germany (2017–2030)
Figure 14: Total Diagnosed Prevalent Population of Contact Dermatitis in France (2017–2030)
Figure 15: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in France (2017–2030)
Figure 16: Gender-specific Diagnosed Prevalent Population of CD in France (2017–2030)
Figure 17: Age-specific Diagnosed Prevalent Population of CD in France (2017–2030)
Figure 18: Type-specific Diagnosed Prevalent Population of CD in France (2017–2030)
Figure 19: Total Diagnosed Prevalent Population of Contact Dermatitis in Italy (2017–2030)
Figure 20: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Italy (2017–2030)
Figure 21: Gender-specific Diagnosed Prevalent Population of CD in Italy (2017–2030)
Figure 22: Age-specific Diagnosed Prevalent Population of CD in Italy (2017–2030)
Figure 23: Type-specific Diagnosed Prevalent Population of CD in Italy (2017–2030)
Figure 24: Total Diagnosed Prevalent Population of Contact Dermatitis in Spain (2017–2030)
Figure 25: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Spain (2017–2030)
Figure 26: Gender-specific Diagnosed Prevalent Population of CD in Spain (2017–2030)
Figure 27: Age-specific Diagnosed Prevalent Population of CD in Spain (2017–2030)
Figure 28: Type-specific Diagnosed Prevalent Population of CD in Spain (2017–2030)
Figure 29: Total Diagnosed Prevalent Population of Contact Dermatitis in the United Kingdom (2017–2030)
Figure 30: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in the United Kingdom (2017–2030)
Figure 31: Gender-specific Diagnosed Prevalent Population of CD in the United Kingdom (2017–2030)
Figure 32: Age-specific Diagnosed Prevalent Population of CD in the United Kingdom (2017–2030)
Figure 33: Type-specific Diagnosed Prevalent Population of CD in the United Kingdom (2017–2030)
Figure 34: Total Diagnosed Prevalent Population of Contact Dermatitis in Japan (2017–2030)
Figure 35: Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution in Japan (2017–2030)
Figure 36: Gender-specific Diagnosed Prevalent Population of CD in Japan (2017–2030)
Figure 37: Age-specific Diagnosed Prevalent Population of CD in Japan (2017–2030)
Figure 38: Type-specific Diagnosed Prevalent Population of CD in Japan (2017–2030)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook